# Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

> **NCT04780347** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 92 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Albumin-bound paclitaxel plus capecitabine
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT04780347
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-15
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-02-25
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04780347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04780347, "Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04780347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*